Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Narrative (Details)

v3.19.2
Revenue Recognition - Narrative (Details) - USD ($)
3 Months Ended 6 Months Ended 18 Months Ended 51 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Mar. 31, 2019
Mar. 31, 2019
Dec. 31, 2018
Disaggregation of Revenue [Line Items]              
Prior period performance obligation revenue recognized     $ 14,300,000 $ 15,700,000      
Overpayment reimbursement liability $ 30,500,000   30,500,000       $ 35,900,000
Revenue recognized   $ 4,800,000   8,500,000 $ 0    
Total revenues 226,368,000 263,685,000 448,820,000 518,598,000      
Contract liability 54,100,000   54,100,000       $ 91,100,000
Rayaldee              
Disaggregation of Revenue [Line Items]              
Revenue recognized 5,700,000   11,500,000        
Total revenues     27,580,000        
Transfer of intellectual property and other              
Disaggregation of Revenue [Line Items]              
Total revenues 19,230,000 19,107,000 37,490,000 34,855,000      
Pfizer | Products              
Disaggregation of Revenue [Line Items]              
Revenue recognized           $ 0  
Contract liability 47,500,000   47,500,000        
Pfizer | Products | Transfer of intellectual property and other              
Disaggregation of Revenue [Line Items]              
Total revenues $ 18,200,000 $ 16,300,000 $ 35,600,000 $ 31,000,000.0